Induction of cancer stem cell properties in colon cancer cells by defined factors

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Oshima, Nobu ^a,b   Yamada, Yasuhiro ^a   Nagayama, Satoshi ^b,c   Kawada, Kenji ^b   Hasegawa, Suguru ^b   Okabe, Hiroshi ^b   Sakai, Yoshiharu ^b   Aoi, Takashi ^a,d  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR SOX2; ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; KRUPPEL LIKE FACTOR; POU5F1 PROTEIN, HUMAN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CANCER TISSUE; CANCER TRANSPLANTATION; CARCINOGENICITY; CELL DIFFERENTIATION; CELL ISOLATION; CELL LINEAGE; COLON CANCER; CONTROLLED STUDY; CULTURE MEDIUM; DRUG TARGETING; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MARKER GENE; MOUSE; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIMARY CELL LINE; TERATOMA; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; COLON TUMOR; DRUG RESISTANCE; GENETICS; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; RETROVIRUS; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PHENOTYPE; RETROVIRIDAE; SOXB1 TRANSCRIPTION FACTORS; TRANSDUCTION, GENETIC;

EID: 84904035128     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101735     Document Type: Article

References (43)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111. (Pubitemid 33041634)
2. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
3. Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nature medicine 17: 313-319.
4. Chen L, Kasai T, Li Y, Sugii Y, Jin G, et al. (2012) A model of cancer stem cells derived from mouse induced pluripotent stem cells. PloS one 7: e33544.
5. Nishi M, Sakai Y, Akutsu H, Nagashima Y, Quinn G, et al. (2013) Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene.
6. Zhang J, Espinoza LA, KindersRJ, Lawrence SM, Pfister TD, et al. (2013) NANOG modulates stemness in human colorectal cancer. Oncogene 32: 4397-4405.
7. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872. (Pubitemid 350138099)
8. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, et al. (2008) Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nature biotechnology 26: 101-106.
9. Matsui T, Takano M, Yoshida K, Ono S, Fujisaki C, et al. (2012) Neural stem cells directly differentiated from partially reprogrammed fibroblasts rapidly acquire gliogenic competency. Stem Cells 30: 1109-1119.
10. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, et al. (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature medicine 7: 1028-1034. (Pubitemid 32937383)
11. Kondo T, Setoguchi T, Taga T (2004) Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proceedings of the National Academy of Sciences of the United States of America 101: 781-786. (Pubitemid 38121035)
12. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, et al. (2006) Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24: 506-513. (Pubitemid 44464754)
13. Todaro M, Francipane MG, Medema JP, Stassi G (2010) Colon cancer stem cells: promise of targeted therapy. Gastroenterology 138: 2151-2162.
14. Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG (2012) Colorectal cancer stem cells. Stem Cells 30: 363-371.
15. O'Brien CA, Pollett A,Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110. (Pubitemid 46067310)
16. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115. (Pubitemid 46067311)
17. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America 104: 10158-10163. (Pubitemid 47175279)
18. Du L,Wang H, He L, Zhang J,Ni B, et al. (2008) CD44 is of Functional Importance for Colorectal Cancer Stem Cells. Clin Cancer Res 14: 6751-6760.
19. Pang R, Law WL, Chu ACY, Poon JT, Lam CSC, et al. (2010) A Subpopulation of CD26+ Cancer Stem Cells with Metastatic Capacity in Human Colorectal Cancer. Cell Stem Cell 6: 603-615.
20. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, et al. (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69: 3382-3389.
21. Ding XW, Wu JH, Jiang CP (2010) ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life sciences 86: 631-637.
22. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, et al. (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337: 730-735.
23. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, et al. (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65: 6207-6219. (Pubitemid 40994406)
24. Challen GA, Little MH (2006) A side order of stem cells: the SP phenotype. Stem cells 24: 3-12.
25. Gao N, White P, Kaestner KH (2009) Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2. Developmental cell 16: 588-599.
26. Chan CW, Wong NA, Liu Y, Bicknell D, Turley H, et al. (2009) Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1. Proceedings of the National Academy of Sciences of the United States of America 106: 1936-1941.
27. Tot T (2002) Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer 38: 758-763.
28. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, et al. (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clinical cancer research : an official journal of the American Association for Cancer Research 11: 3766-3772.
29. Moll R, Lowe A, Laufer J, Franke WW (1992) Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. The American journal of pathology 140: 427-447.
30. Bayrak R, Haltas H, Yenidunya S (2012) The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody. Diagn pathol 7: 9.
31. Ee HC, Erler T, Bhathal PS, Young GP, James RJ (1995) Cdx-2 homeodomain protein expression in human and rat colorectal adenoma and carcinoma. The American journal of pathology 147: 586-592.
32. Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458: 719-724.
33. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nature reviews Cancer 5: 275-284. (Pubitemid 40488633)
34. Inoda S, Hirohashi Y, Torigoe T, Morita R, Takahashi A, et al. (2011) Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. The American journal of pathology 178: 1805-1813.
35. Rosen JM, Jordan CT (2009) The increasing complexity of the cancer stem cell paradigm. Science 324: 1670-1673.
36. Werling RW, Yaziji H, Bacchi CE, Gown AM (2003) CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. The American journal of surgical pathology 27: 303-310. (Pubitemid 36245795)
37. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, et al. (2008) Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 14: 4085-4095.
38. Schoenhals M, Kassambara A, Vos JD, Hose D, Moreaux J, et al. (2009) Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 383: 157-162.
39. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, et al. (2009) Correlation of CD133, OCT4, and SOX2 in Rectal Cancer and Their Association with Distant Recurrence After Chemoradiotherapy. Annals of Surgical Oncology 16: 3488-3498.
40. Neumann J, Bahr F, Horst D, Kriegl L, Engel J, et al. (2011) SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer. BMC Cancer 11: 518.
41. Yu F, Li J, Chen H, Fu J, Ray S, et al. (2011) Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 30: 2161-2172.
42. Matsuoka J, Yashiro M, Sakurai K, Kubo N, Tanaka H, et al. (2012) Role of the Stemness Factors Sox2, Oct3/4, and Nanog in Gastric Carcinoma. J Surg Res 174: 130-135.
43. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, et al. (2009) Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460: 1132-1135.